SINGAPORE, May 23, 2018: Morgan Lewis represented MediSix Therapeutics, a development-stage cell therapy company targeting T-cell leukemia and lymphoma, in a $20 million Series A funding.
The financing, announced on May 15, was led by Lightstone Ventures with participation from Temasek and Osage University Partners.
The Morgan Lewis team representing MediSix was led by partners Jeffry Mann, Scott Karchmer and Edward Bennett, with support from associates Corey Mueller and Jeremiah Huang.
Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.